June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Comparison of the effect of Dexamethasone drug delivery system in macular edema in patients with uveitis or retinal vein occlusion
Author Affiliations & Notes
  • Thomas Ness
    University Eye Hospital, University of Freiburg, Freiburg, Germany
  • Daniel Boehringer
    University Eye Hospital, University of Freiburg, Freiburg, Germany
  • Amelie Pielen
    University Eye Hospital, University of Freiburg, Freiburg, Germany
  • Sonja Heinzelmann
    University Eye Hospital, University of Freiburg, Freiburg, Germany
  • Footnotes
    Commercial Relationships Thomas Ness, Abbott GmbH & Co KG (C), Abbott GmbH & Co KG (R), Novartis Pharma GmbH (C), Novartis Pharma GmbH (R), Novartis Pharma GmbH (S), Santen GmbH (R), Pharm Allergan (S); Daniel Boehringer, None; Amelie Pielen, Novartis Pharma GmbH (F), Novartis Pharma GmbH (C), Pharm Allergan GmbH (C), Bayer Healthcare (F), GlaxoSmithKline (F), Pfizer GmbH (F), Alcon Pharma GmbH (F), Genentech (F); Sonja Heinzelmann, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5388. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Thomas Ness, Daniel Boehringer, Amelie Pielen, Sonja Heinzelmann; Comparison of the effect of Dexamethasone drug delivery system in macular edema in patients with uveitis or retinal vein occlusion. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5388.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To compare the effect of a dexamethasone drug delivery system (Ozurdex) on macular edema in patients with persistent macular edema due to inflammation or retinal vein occlusion.

Methods: Eighty-four patients (35 uveitis/49 retinal vein occlusion) injected with Ozurdex from September 2010 to November 2012 at an academic center were included. Thirty-four eyes were reinjected up to 4 times. Visual acuity, total macular volume, rate of relapses, treatment survival analysis and side effects were evaluated retrospectively .

Results: The primary response rate to Ozurdex (visual acuity and/or reduction of total macular volume) was 100% in uveitis patients and 82% in retinal vein occlusion patients (p<0.01). In both groups, visual acuity improved and total macular volume decreased significantly. After the first and second injection the mean time interval until relapse was 145/143 days in uveitis and 160/160 days in retinal vein occlusion, respectively. It seemed to be longer after the third injection in uveitis (367 days), while it was unchanged in retinal vein occlusion (147 days). The rate of cataract formation and intraocular pressure rise was low in both groups.

Conclusions: After the injection of Ozurdex macular edema in uveitis responded more frequently than macular edema in retinal vein occlusion. In contrast to retinal vein occlusion, in uveitis the effect of the injection seemed to be prolonged after at least three injections. Since there were a low number of complications, Ozurdex is an alternative to treat patients with persistent macular edema in uveitis.

Keywords: 746 uveitis-clinical/animal model • 749 vascular occlusion/vascular occlusive disease • 505 edema  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×